N-[(3R,6S)-6-(2,3-二氟苯基)六氢-2-氧代-1-(2,2,2-三氟乙基)-1H-氮杂卓-3-基]-4-(2,3-二氢-2-氧代-1H-咪唑并[4,5-b]吡啶-1-基)-1-哌啶甲酰胺

Telcagepant (INN) (code name MK-0974) is a calcitonin gene-related peptide receptor antagonist which was an investigational drug for the acute treatment and prevention of migraine, developed by Merck & Co. In the acute treatment of migraine, it was found to have equal potency to rizatriptan and zolmitriptan in two Phase III clinical trials. The company has now terminated development of the drug.